Possible agent for COVID-19 treatment: Rifampicin

Rifampicin is a promising drug for the treatment of coronavirus disease 2019 based on its antiviral properties and recent in silico studies. In silico studies can serve as a foundation for further studies.

Detalles Bibliográficos
Autores principales: Aydin, Ozlem Celik, Aydın, Sonay, Barun, Sureyya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523331/
https://www.ncbi.nlm.nih.gov/pubmed/36188747
http://dx.doi.org/10.5501/wjv.v11.i5.391
_version_ 1784800264540127232
author Aydin, Ozlem Celik
Aydın, Sonay
Barun, Sureyya
author_facet Aydin, Ozlem Celik
Aydın, Sonay
Barun, Sureyya
author_sort Aydin, Ozlem Celik
collection PubMed
description Rifampicin is a promising drug for the treatment of coronavirus disease 2019 based on its antiviral properties and recent in silico studies. In silico studies can serve as a foundation for further studies.
format Online
Article
Text
id pubmed-9523331
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-95233312022-10-01 Possible agent for COVID-19 treatment: Rifampicin Aydin, Ozlem Celik Aydın, Sonay Barun, Sureyya World J Virol Letter to the Editor Rifampicin is a promising drug for the treatment of coronavirus disease 2019 based on its antiviral properties and recent in silico studies. In silico studies can serve as a foundation for further studies. Baishideng Publishing Group Inc 2022-09-25 2022-09-25 /pmc/articles/PMC9523331/ /pubmed/36188747 http://dx.doi.org/10.5501/wjv.v11.i5.391 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Letter to the Editor
Aydin, Ozlem Celik
Aydın, Sonay
Barun, Sureyya
Possible agent for COVID-19 treatment: Rifampicin
title Possible agent for COVID-19 treatment: Rifampicin
title_full Possible agent for COVID-19 treatment: Rifampicin
title_fullStr Possible agent for COVID-19 treatment: Rifampicin
title_full_unstemmed Possible agent for COVID-19 treatment: Rifampicin
title_short Possible agent for COVID-19 treatment: Rifampicin
title_sort possible agent for covid-19 treatment: rifampicin
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523331/
https://www.ncbi.nlm.nih.gov/pubmed/36188747
http://dx.doi.org/10.5501/wjv.v11.i5.391
work_keys_str_mv AT aydinozlemcelik possibleagentforcovid19treatmentrifampicin
AT aydınsonay possibleagentforcovid19treatmentrifampicin
AT barunsureyya possibleagentforcovid19treatmentrifampicin

Ejemplares similares